°¡Å縯´ëÇб³ ¿©Àǵµ¼º¸ðº´¿ø Á¤½Å°Ç°ÀÇÇаú ¿ì¿µ¼·(»çÁø) ±³¼ö°¡ Áö³ 9¿ù 8ÀÏ ¹Ð·¹´Ï¾ö ¼¿ï ÈúÆ° È£ÅÚ¿¡¼ °³ÃÖµÈ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ÃÑȸ¿¡¼ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ ¿ÀÃ÷Ä« Çмú»óÀ» ¼ö»óÇß´Ù.
¿ì¿µ¼· ±³¼ö´Â ÃÖ±Ù 3³â°£ ´ë»ç¼º ÁõÈıº°ú ¿ì¿ïÀå¾ÖÀÇ Ä¡·á ¹ÝÀÀÀÇ ¿¬°ü¼ºÀ» ÀÔÁõÇÑ ¡®Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea¡¯, ¾ç±Ø¼ºÀå¾Ö¿¡¼ ±âÁ¸ Ä¡·á·Î ÃæºÐÈ÷ Ä¡·áµÇÁö ¾ÊÀº ¾ÆÀÓ»óÀû(subclinical) Áõ»óÀÇ Ä¡·á ¹æ¾ÈÀ» Ž»öÇÑ ¡®Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder¡¯ µî 1ÀúÀÚ ³í¹® 14ÆíÀ» Æ÷ÇÔÇÑ 30ÆíÀÇ Á¤½Å¾à¹° °ü·Ã ³í¹®À» SCI±Þ ±¹Á¦ÇмúÁö¿¡ ¹ßÇ¥ÇÏ¿© ±¹³» Á¤½Å¾à¹°ÇÐ ºÐ¾ßÀÇ ¹ßÀü¿¡ ±â¿©ÇÑ Á¡À» ÀÎÁ¤¹Þ¾Ò´Ù.
´ëÇÑÁ¤½Å¾à¹°ÇÐȸ ¿ÀÃ÷Ä« Çмú»óÀº ½Å°æÁ¤½Å¾à¹°ÇÐ ºÐ¾ßÀÇ ¿¬±¸ ÁøÈïÀ» À§ÇÏ¿© 2002³â Á¦Á¤µÈ »óÀ¸·Î, ÃÖ±Ù 3³â°£ÀÇ Çмú ¹× ¿¬±¸ ¾÷ÀûÀÌ ¶Ù¾î³ ¿¬±¸ÀÚ¸¦ ¼±Á¤ÇÏ¿© ½Ã»óÇÏ°í ÀÖ´Ù.